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Medical Mycology February 2011, 49, 132–142 Candida albicans is one of the most important opportunistic fungal pathogens. It can 
cause serious fungal diseases in immunocompromised patients, including those with 
cancer. Treatment failures due to the emergence of drug-resistant  C. albicans strains have 
become a serious clinical problem. Resistance incidents were often mediated by fungal 
effl ux pumps which are closely related to the human ABC transporter P-glycoprotein 
(P-gp). P-gp is often overexpressed in cancer cells and confers resistance to many cyto-
toxic drugs. We examined whether cytotoxic drugs commonly used for cancer treatment 
(doxorubicin and cyclophosphamide) could alter the expression of genes responsible for 
the development of fl uconazole resistance in  Candida cells in the way they can infl uence 
homologous genes in cancer cell lines. ABC transporters ( CDR1 and  CDR2 ) and other 
resistance genes ( MDR1 and  ERG11) were tested by real-time PCR for their expres-
sion in  C. albicans cells at the mRNA level after induction by antineoplastic drugs. 
The results were confi rmed by a lacZ gene reporter system and verifi ed at the protein 
level using GFP and immunoblotting. We showed that doxorubicin is a potent inducer 
of  CDR1/CDR2 expression in  C. albicans at both the mRNA and protein level and thus 
causes an increase in fl uconazole MIC values. However, cyclophosphamide, which is 
not a substrate of human P-gp, did not induce ABC transporter expression in  C. albicans . 
Neither doxorubicin nor cyclophosphamide could infl uence the expression of the other 
resistance genes ( MDR1 and  ERG11) . The induction of  CDR1/CDR2 by doxorubicin in 
 C. albicans and the resulting alteration of antifungal susceptibility might be of clinical 
relevance for the antifungal treatment of  Candida infections occurring after anticancer 
chemotherapy with doxorubicin. ,
g Keywords  Candida albicans ,  azoles ,  ABC transporter ,  resistance mechanisms ,  
doxorubicin  Introduction 
 Candida spp. infections have increased in incidence among 
immunocompromised patients in recent years and have now 
become the fourth most common bloodstream infections 
[1 – 3]. These pathogens pose a serious threat to chemother-
apy patients whose immune system is compromised by d in fi nal revised form 5 July 2010; 
harit é  – Universit ä tsmedizin Berlin, 
artment, Division of Oncology/Hema-
 Germany. Tel:   49 (0)30450613124; 
rzegorz.kofl a@charite.de leukemia or other types of cancer [4,5]. Some molecular 
processes are linked to the emergence of intractable fl ucon-
azole-resistant  Candida albicans infections [6,7], the most 
important of which are; (i) upregulation of  CDR1 and  CDR2 , 
genes encoding multidrug effl ux transporters of the ATP-
binding cassette (ABC) transporter family, (ii) upregulation 
of  MDR1 , a major facilitator transporter gene, and (iii) tran-
scription increase of  ERG11 , a gene coding for the drug 
target enzyme sterol 14 α -demethylase or  ERG11 point muta-
tions. The transporter proteins increase active effl ux of anti-
fungal agents, and upregulation of  ERG11 raises the amount 
of the target enzyme, making the intracellular azole concen-
tration insuffi cient to inhibit the enzyme activity [7 – 9]. DOI: 10.3109/13693786.2010.512022
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as surgery, radiotherapy and chemotherapy. Multidrug 
resistance (MDR) of neoplastic tissues is a persistent prob-
lem in cancer chemotherapy [10]. The main cause of MDR 
is overexpression of P-glycoprotein (P-gp), a member of 
the human ABC transporter family. This transporter family 
has broad substrate specifi city for several substances, 
including anticancer drugs, linear and cyclic peptides, HIV 
protease inhibitors, and several other molecules [11,12]. 
The putative physiological function of P-gp is to protect 
cells from toxins and xenobiotics. Substrates of these effl ux 
pumps are cytotoxic compounds of natural origin such as 
anthracyclines (doxorubicin, daunorubicin), vinca alka-
loids (vincristine, vinblastine), epipodophyllotoxins 
(etoposide, teniposide), taxane, and amsacrine. Doxorubi-
cin, daunomycin, vincristine and mitoxantrone were 
shown to induce P-gp mRNA in rat, mouse and human cell 
lines [13,14]. 
 The fungal  CDR effl ux pumps are functionally and struc-
turally related to the human P-gp responsible for MDR. The 
aim of this study was to investigate whether antineoplastic 
drugs used in cancer therapy could affect the expression 
levels of genes responsible for antifungal drug resistance. 
We tested two commonly used cytostatic drugs, i.e., doxo-
rubicin (intercalating agent and substrate of human P-gp) 
and cyclophosphamide (alkylating agent and not a substrate 
of human P-gp). Using a real-time PCR system developed 
in our laboratory, ABC transporters ( CDR1 and  CDR2 ) and 
other resistance genes like  MDR1 and  ERG11 were tested 
for their expression in  C. albicans cells at the mRNA level 
after induction by the above-mentioned drugs [15]. All PCR 
results were obtained with three pairs of clinical  C. albicans 
isolates from three individuals with HIV infection. Each pair 
of isolates consisted of an azole-sensitive (pretreatment) iso-
late and a second isolate that had acquired resistance during 
fl uconazole treatment for recurrent oropharyngeal candido-
sis (OPC). In addition, a  TAC1 knock-out mutant and its 
paternal strain were tested by similar approaches.  TAC1 
(transcriptional activator of  CDR genes) is essential for con-
trolling expression of  CDR1 and  CDR2 [16]. The PCR 
results were confi rmed by a   -galactosidase (lacZ) gene 
reporter system and verifi ed at the protein level by GFP 
fusion proteins and Western blot analysis as previously 
described [16,17]. 
 Materials and methods 
 Strains and culture conditions 
 C. albicans isolates used for gene expression analyses are 
listed in Table 1. The isolates were obtained from three 
AIDS patients by oral washings with sterile 0.9% NaCl 
solution during recurrent episodes of OPC before and after © 2011 ISHAM, Medical Mycology, 49, 132–142fl uconazole treatment. Fluconazole-susceptible isolates 
(F1, B1, and Gu1) were recovered before initiating fl ucon-
azole treatment. The second set of isolates (F5, B5, Gu5) 
was recovered from the same three individuals during 
fl uconazole-refractory episodes (no response to 400 mg/
day fl uconazole) later in the course of HIV infection. The 
expression levels of  CDR genes,  MDR1 and  ERG11 genes 
in these isolates, as well as the MIC values have been 
described in previously published studies [9,18].  C. albi-
cans isolates were classifi ed as susceptible to fl uconazole 
with MICs of   8.0  μ g/ml, dose-dependently susceptible 
with MICs of   8.0 to   32  μ g/ml, and resistant within 
MICs of   32  μ g/ml [19]. 
 The  C. albicans  tac1 Δ / Δ mutant and its paternal strain 
CAF2-1 have been described in a previous publication 
[16]. The isolates were kept as frozen stocks at   80 ° C 
and subcultured on YPD agar medium in plates (10 g/l 
yeast extract, 20 g/l peptone, 20 g/l glucose, 15 g/l agar) 
at 30 ° C.  
 RNA extraction and cDNA synthesis including DNase digest 
 Before RNA extraction, the  C. albicans isolates were cul-
tured in YPD broth overnight at 37 ° C. Portions of growth 
from the overnight culture were used to inoculate fresh 
YPD broth, and cells were allowed to grow for another 
2 h until mid-log phase. Cytotoxic drugs were added in 
defi ned (therapeutic) concentrations (20  μ g/ml of doxoru-
bicin, 20  μ g/ml of cyclophosphamide) to samples desig-
nated for treatment and incubated either for 90 min or 
24 h. Each strain was concomitantly cultured at both time 
points without the drug as a control. Fluconazole was not 
added to the cultures. 
 RNA was isolated using RNA-PLUS ™ (Total RNA 
Extraction Solution, Qbiogene) according to the manufac-
turer ’ s guidelines. Before starting the RNA isolation pro-
tocol, the fungal cell walls were mechanically disrupted 
using Lysing Matrix C tubes and the FastPrep ® FP120A 
instrument (Qbiogene). The RNA concentrations were 
determined by photometry. One microgram of RNA in a 
19  μ l volume was used for cDNA synthesis. After adding 
1  μ g of oligo(dT) primer (Invitrogen, Karlsruhe, Germany), 
the samples were incubated for 10 min at 75 ° C. The fol-
lowing components were added to each sample: 8  μ l of 
5   fi rst strand buffer, 4  μ l of 0.1 M dithiothreitol (both 
Invitrogen), 4  μ l of NTPs (10 mM each) (GeneAmp ® , 
Applied Biosystems, Darmstadt, Germany), 20 U of RNa-
sin ® Plus Rnase Inhibitor (Promega, Mannheim, Germany) 
and 1  μ l of DNase (Roche, Mannheim, Germany) to elim-
inate possible DNA contamination. The mixture was incu-
bated at 37 ° C for 30 min and at 75 ° C for 5 min to inactivate 
the DNase. For the fi nal reaction, 20 U of RNasin ® Plus 
RNase Inhibitor (Promega) and 200 U of SuperScript ™ 
 134 Kofl a  et al . RNase H - Reverse Transcriptase (Invitrogen) were added 
to each sample, followed by incubation at 42 ° C for 1 h 
after 5 min at 94 ° C to inactivate the reverse transcriptase. 
The cDNA was stored at  – 20 ° C until further use. 
 Gene expression analysis 
 Gene expression analyses were carried out using the real-
time PCR system (LightCycler ® 480, Roche) and 96-well 
microtiter plates. The expressions of the following genes 
were analyzed:  CDR1 ,  CDR2 ,  MDR1 and  ERG11 . Primers 
and probes (TIB Molbiol, Berlin, Germany) are listed in 
Table 2. Each cDNA sample was analyzed in duplicate and 
normalized against expression of the  C. albicans reference 
gene  ACT1 . Each 25  μ l PCR reaction contained: 10   PCR 
buffer (20 mM Tris-HCL (pH 8.4), 500 mM KCL), 4.5 mM 
MgCl 2 , 200  μ M dNTP, 400 nM sense and 400 nM anti-
sense primer, 120 nM probe with a reporter and quencher 
dye, and 0.75 U of platinum  Taq DNA polymerase (Invit-
rogen). Finally, 1  μ l of template cDNA was added to 
each PCR reaction. PCR conditions were: 3 min at 95 ° C 
to denature the template and activate the polymerase, 
followed by 45 cycles of 95 ° C for 15 s, 60 ° C for 30 s 
(primer/probe annealing) and 72 ° C for 30 s (extension). 
The crossing point (C P ) values were calculated using the 
LightCycler ® 480 Software (Roche). Relative quantifi ca-
tion was performed applying the  Δ C T method [15]. The 
whole experiment, from culturing the isolates in YPD broth 
to gene expression analyses, was carried out on two differ-
ent occasions.    -galactosidase (lacZ) reporter system 
 The lacZ reporter system for quantifying  MDR1 and  CDR2 
expression has been described elsewhere [20]. To generate 
 MDR1 – lacZ and  CDR2 – lacZ fusions used in drug induc-
tion assays, the 999 bp  MDR1 and 903 bp  CDR2 promoters 
were fi rst amplifi ed by PCR using the Taq DNA poly-
merase (Roche) with primers MDR1-5 ′ -999-KPN and 
MDR1-3 ′ -PST or primers CDR2-KPN and CDR2-PST. 
The generated fragments were cloned into pAU36 after 
digestion with  Kpn I and  Pst I [21]. The resulting plasmids 
(pBR1 and pDS295) were digested with either  Nru I for the 
 MDR1 – lacZ fusion or  Sna BI for the  CDR2 – lacZ fusion 
prior to transformation into  C. albicans , which enabled 
their integration at the  MDR1 and  CDR2 loci. Both fusions 
were integrated by double crossover at the  MDR1 and 
 CDR2 loci of a  cdr1 Δ / Δ mutant  C. albicans strain. 
 Measurement of lacZ reporter activities . Cells were grown 
overnight in 3 ml of YEPD at 30 ° C under constant agitation. 
Cultures were then diluted in 5 ml of fresh medium to obtain 
a cell density of approximately 5   106 cells/ml and were 
regrown under agitation until the density reached 1.5   107 
cells/ml. At this point, 1 ml aliquots from drug-unexposed 
cultures were centrifuged at 4 ° C for 5 min at 5,500 rpm. 
 Exposure to cytotoxic drugs . At various time intervals,  C. 
albicans strains were exposed to three fi xed concentrations 
(10, 20, 40  μ g/ml) of different cytotoxic drugs at 30 ° C under 
constant agitation. Benomyl was used as positive control for 
 MDR1 induction and was measured by  MDR1 - lacZ reporter. 
Cell density was measured after drug exposure, and cultures Table 1 Strains and clinical isolates of Candida albicans used in this study.Isolates
Date of isolation
(mo/day/yr)
MICFlu 
(μg/ml) Description ReferencePatient 1 F1 07/05/90 3.12 – [9]
F5 01/14/91 50 Enhanced MDR1 and ERG11 mRNA levels
Patient 2 Gu1 01/24/90 0.78 – [18]
Gu5 11/02/95  100 Enhanced CDR1, CDR2 mRNA levels
Patient 3 B1 09/27/93 0.39 – [18]
B5 11/17/94 50 Enhanced MDR1 mRNA levelStrains Parent strain MICFlu (μg/ml) Description ReferenceCAF2-1 SC5314  0.125 Parent strain of TAC1 null mutant [35]
tac1Δ/Δ DSY2883  0.125 TAC1 null mutant [16]
MDR1-lacZ DSY449  0.125 MDR1 promotor fusion with lacZ [36]
CDR2-lacZ DSY449  0.125 CDR2 promotor fusion with lacZ [36]
DSY3040 DSY294 0.25 Parental strain of Cdr1p- and Cdr2p-GFP strains
 (azole susceptible)
[22]
DSY3041 DSY296 64 Parental strain of Cdr1p- and Cdr2p-GFP strains
 (azole resistant)
[22]
DSY3098 DSY3040 0.25 Cdr1p-GFP (azole susceptible) This study
DSY3108 DSY3041 64 Cdr1p-GFP (azole resistant) This study
DSY3091 DSY3040 0.25 Cdr2p-GFP (azole susceptible) This study
DSY3092 DSY3041 64 Cdr2p-GFP (azole resistant) This study© 2011 ISHAM, Medical Mycology, 49, 132–142
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pellets were washed with 1 volume Z buffer (60 mM 
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) 
and centrifuged at 4 ° C for another 10 min. The washed cell 
pellets were resuspended in 150  μ l of Z buffer supplemented 
with 38.6 mM mercaptoethanol. After adding 50  μ l of chlo-
roform and 20  μ l 0.1% SDS, cells were disrupted by vortex-
ing. Aliquots preheated at 30 ° C after adding 700  μ l ONPG 
(1 mg/ml; Sigma) in Z buffer supplemented with mercapto-
ethanol. The mixtures were incubated at 37 ° C until they 
turned yellow (20 min to 3 h). The enzyme was inactivated 
by adding 500  μ l of 1 M Na2CO3. The mixtures were cen-
trifuged at 13,000 rpm for 10 min, and the OD420 was read. 
The lacZ activities were calculated using the following equa-
tion: lacZ activity (Miller units)   (1000   OD420)/ 
( t    v   OD600), where  t is the time of reaction expressed 
in min and  v is the culture volume assayed in ml. The exper-
iment was repeated three times. 
 GFP fusion protein assay 
 Green fl uorescent protein (GFP) was fused to  CDR1 and 
 CDR2 ORF constructs introduced into azole-sensitive © 2011 ISHAM, Medical Mycology, 49, 132–142and azole-resistant  C. albicans isolates. Cdr1p- and 
Cdr2p-GFP fusions were constructed by insertion of a 
SmaI site replacing the stop codons of each ORF. For the 
Cdr1p-GFP fusion,  CDR1 PCR fragments corresponding 
to the C- terminal end of the protein were generated from 
a cloned  CDR1 in pDS243 with primer pair CDR1-Hi and 
CDR1-SMA1 and primer pair CDR1-Kp and CDR1-
SMA2. Primer sequences are listed in Table 2. The two 
PCR fragments were next used in a sewing PCR with the 
external primers CDR1-Hi and CDR1-Kp and cloned into 
pDS505 after HindIII and KpnI digestion. pDS505 is 
based on pMTL21 and contains the  C. albicans  URA3 
gene at the SacI site. The resulting plasmid (pDS605) was 
containing a SmaI site into which the GFP ORF was intro-
duced in frame with the C-terminal end of Cdr1p. The result-
ing plasmid, pDS610, was linearized with NcoI and used to 
transform  C. albicans strains DSY3040 and DSY3041, 
which are Ura - derivatives of the azole-susceptible and 
azole-resistant strains DSY294 and DSY296, respec-
tively [22]. The resulting strains were DSY3098 and 
DSY3108, into which the Cdr1p-GFP fusion is in-frame 
insertion at the  CDR1 genomic locus. 
 The same strategy was used for the Cdr2p-GFP fusion. 
 CDR2 PCR fragments corresponding to the C-terminal end 
of the protein were generated from a cloned  CDR2 in 
pDS246 with primer pair CDR2-Hi and CDR2-SMA1 and 
primer pair CDR2-Kp and CDR2-SMA2. Primer sequences 
are listed in Table 2. The two PCR fragments were next 
used in a sewing PCR with the external primers CDR2-Hi 
and CDR2-Kp and cloned into pDS505 after HindIII 
and KpnI digestion. The resulting plasmid (pDS685) 
was containing a SmaI site into which the GFP ORF was 
introduced in frame with the C-terminal end of Cdr2p. The 
resulting plasmid, pDS706, was linearized with ClaI 
and used to transform  C. albicans strain DSY3040 and 
DSY3041. The resulting strains were DSY3091 and 
DSY3092, into which the Cdr2p-GFP fusion is in-frame 
insertion at the  CDR2 genomic locus [22 – 24]. 
 Transformants were grown with or without doxorubicin 
at a fi xed concentration of 20  μ g/ml in the logarithmic 
phase, and GFP fl uorescence was visualized by micros-
copy. Fluorescence microscopy was performed with a 
Zeiss Axioplan microscope equipped for epifl uorescence 
microscopy with a 100-W mercury high-pressure bulb and 
Zeiss fi lter sets 9 (for GFP). A DX30 digital camera with 
high resolution (Kappa Messtechnik GmbH, Gleichen, 
Germany) was used to record images. 
 Immunoblot 
 Overnight cultures of  C. albicans isolates in YEPD were 
diluted in 5 ml of fresh medium to an OD 600 of 1.0 and 
incubated at 30 ° C until growth reached an OD 600 of 2.0. Table 2 Primers and probes used in this study.Primers/probes SequenceCDR1-Hi 5′-GCGCAAGCTTACATCAGAAATTCCTTATCA
AGTT
CDR1-SMA1 5′-AACTGTTTACCCGGGTTTCTTATTTTTTTTC
TCTCTGTTACC
CDR1-Kp 5′-GCGCGGTACCTACACAATTTTGCAACGGA
AGAGTCGG
CDR1-SMA2 5′-AATAAGAAACCCGGGTAAACAGTTTGTTT
TTTGACATGGTGG
CDR2-Hi 5′-GCGCAAGCTTATGTACAGATGTAATCCATT
CACT
CDR2-SMA1 5′-AGACCCCATCCCGGGTTTTTTCATCTTCTT
TTCATTACC
CDR2-Kp 5′-GCGCGGTACCAAGTTGTTTTAACTGGGAC
CCTGC
CDR2-SMA2 5′-ATGAAAAAACCCGGGATGGGGTCTTATTT
TACAATTAGTATT
CDR1 Pr1 5′-AGGAATCGACGGATCAC
CDR1 Pr2 5′-GAAAGAGAACCATTACCAGG
CDR1 probe 5′-TTCTCGCAACACCATACCTCAC
CDR2 Pr1 5′-GAAATATTGTCGCTTTATGAAGCTAGAC
CDR2 Pr2 5′-GTAGCAATAGTGGTTGTAACAGCACC
CDR2 probe 5′-TTACCCGTCAAGTTACTCATGACCATGTCC
MDR1 Pr1 5′-GAATATAAATAAAGGCAGCAATGAC
MDR1 Pr2 5′-GGTAACGACAGAATCACAAGTG
MDR1 probe 5′-CATTAGAAATCACCGTTATGGAACCAGTT
ERG11 Pr1 5′-ATGGCTATTGTTGAAACTGTCATTG
ERG11 Pr2 5′-CCCTTTACCGAAAACTGGAGTAG
ERG11 probe 5′-CATGACCTTTTGGACCTAAATAAACCGTC
ACT1 Pr1 5′-TTCATTGTAAAAAGTGTGATGC
ACT1 Pr2 5′-ATGGACGGTGAAGAAGTT
ACT1 probe 5′-ATCGATAACGGTTCTGGTATGTGTAA
 136 Kofl a  et al . Cells were then incubated for 90 min with or without dox-
orubicin (20  μ g/ml) or for 30 min with and without fl u-
phenazine (20  μ g/ml) as a positive control. Cultures were 
then pelleted, resuspended in 1 ml H 2 O and lysed for 10 
min at 4 ° C by adding 150  μ l Yex ( Y east  ex traction) lysis 
buffer (1.85 M NaOH and 7.5%  β -mercaptoethanol). Lysis 
products were precipitated for 10 min at 4 ° C with 50% 
trichloroacidic acid solution and spun down for 5 min at 
4 ° C. Pellets were resuspended in sample buffer (40 mM 
TrisHCL pH 6.8, 8 M urea, 5% SDS, 0.1 mM EDTA, 1% 
 β -mercaptoethanol, 0.1 g/l bromophenol blue) and neutral-
ized with 100 mM Tris pH 9.5. Proteins were incubated 
for 30 min at 37 ° C and spun down to remove cellular frag-
ments. Proteins were stored at  – 20 ° C until further use. 
 Proteins were denatured for 10 min at 37 ° C before load-
ing in SDS-PAGE (10%). The prestained SDS-PAGE ® 
(BioRad) molecular weight standard was used to assess 
protein molecular weight. The migration was performed 
with running buffer (Tris 1.5 g/l, glycine 7.2 g/l, SDS 0.5 
g/l) at 150 V for 2 h. 
 The migration gels and nitrocellulose transfer mem-
branes (Whatman ® Protran ® ) were soaked in Towbin buffer 
(Tris 25 mM pH 8.3, 192 mM glycine, 15% methanol, 
0.01% SDS). The transfer was performed for 1 h at 75 V. 
The transferred membranes were blocked for 30 min in a 
blocking solution (5% powdered milk, PBST 0.1% (137 
mM NaCl, 2.7 mM KCl, 21.7 mM Na 2 HPO 4 , 1.47 mM 
KH 2 PO 4 , 0.2% Tween 20). After transfer, remaining 
proteins in the polyacrylamide gels were visualized by 
Coomassie Blue staining to control equal loading of pro-
teins of each sample. Blocked membranes were then incu-
bated separately with polyclonal rabbit primary antibodies 
 α -Cdr1p,  α -Cdr2p or  α -Mdr1p (diluted 1:1000 in the block-
ing solution). The membranes were washed three times for 
5 min in PBST, incubated overnight with goat anti-rabbit 
polyclonal secondary antibody coupled to horseradish per-
oxidase (Dako) (diluted 1:3000 in the blocking solution) 
and then washed 3 times for 5 min in PBST. Finally, the 
membranes were incubated for 3 min with the detection 
solution (50% Lumiglo reagent A, 50% Peroxide reagent B 
(Pierce). The luminescence signals were detected by fi lm 
autoradiography (Amersham Hyperfi lm ™ MP). 
 Determination of minimal inhibition concentrations 
 MIC values were determined by two methods. One proto-
col (macrodilution method) followed the recommendations 
of document M27-A of the Clinical and Laboratory Stan-
dards Institute [25]. The other method (microdilution 
method) differs from recommendations of the macrodilu-
tion method and was used to examine MIC values in the 
presence of doxorubicin [7]. For the microdilution protocol 
overnight cultures of  C. albicans strains were diluted 1:100,000 in 200  μ l of fresh YEPD with different fl ucon-
azole concentrations (0.0625 – 128  μ g/ml) and with or with-
out doxorubicin (20  μ g/ml) in 96-well plates. Plates were 
incubated at 34 ° C for 24 h, and the OD was measured at 
600 nm. The MIC 50 to fl uconazole was defi ned as the abil-
ity of a strain grown with fl uconazole to reach 50% of the 
growth of the same strain grown in YEPD alone. The 
experiment was performed in triplicate. 
 Statistical methods 
 Statistical signifi cance (PCR results) was calculated 
using the Mann-Whitney test. The results are expressed 
as means  	 standard deviation and were considered 
 signifi cant at  P  
 0.05. 
 Results 
 Doxorubicin induces CDR1 and CDR2 expression 
in C. albicans 
 CDR1 and  CDR2 expression was tested at the mRNA level 
after induction by antineoplastic drugs at therapeutic con-
centrations. Doxorubicin induced  CDR1 and  CDR2 in 
both sensitive and resistant strains (Fig. 1). The expression 
of  CDR1 and  CDR2 was enhanced signifi cantly in all 
doxorubicin-treated isolates after 90 min. The upregulation 
persisted or increased after 24 h of induction except F1, F5 
and Gu1, in which  CDR2 upregulation after 24 h was not 
detected (Fig. 1). Most of the isolates showed a 2- to 3-fold 
expression increase at the transcriptional level and in some 
cases this difference was even higher.  
 The highest upregulation after 24 h of induction 
was observed in the isolate pair Gu1/5, in which Gu5 
(resistant strain) already exhibited high  CDR1 expression 
levels without drug exposure. Noteworthy is the fact that, 
after doxorubicin exposure, the azole-susceptible strain of 
this pair (Gu1) showed  CDR1 expression levels compa-
rable to those of the resistant isolate. Moreover, the resis-
tant strain (Gu5), which already exhibits intrinsic high 
 CDR1 expression in the absence of doxorubicin, showed 
increased expression principally for  CDR2 (  10-fold 
expression increase after 24 h doxorubicin exposure) 
(Fig. 1). 
 Isolates from the other two individuals (F and B) in 
which the resistant isolates were primarily characterized 
by overexpression of  MDR1 , showed a signifi cant induc-
tion of  CDR genes by doxorubicin in both the fl uconazole 
resistant and the susceptible strain (  2-fold increase) 
(Fig. 1). 
 Since CDR1 and  CDR2 are regulated by the transcrip-
tional factor  TAC1, it is likely that  TAC1 is involved in the 
process of doxorubicin-mediated induction. Consistently, © 2011 ISHAM, Medical Mycology, 49, 132–142
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no signifi cant induction by doxorubicin was observed for 
both  CDR1 and  CDR2 . In contrast, the parental strain was 
still able to respond to doxorubicin treatment by upregula-
tion of  CDR1 and CDR2 (Fig. 2).  
 Doxorubicin had no effect on  MDR1 or  ERG11 expres-
sion in the isolates investigated in this study, which indi-
cated a gene-specifi c effect of doxorubicin in  C. albicans 
(Fig. 1, Fig. 3C). 
 We also examined cyclophosphamide, another fre-
quently used cytostatic drug in cancer therapy which is no 
inducer of human P-gp. Conversely to doxorubicin, no 
effect on the expression of any of the investigated resis-
tance genes could be observed with cyclophosphamide at 
defi ned and physiologically achievable concentrations 
(Fig. 1). 
 Assessing doxorubicin induction by an alternative method 
 The real-time PCR results were confi rmed by a second 
method. With a  lacZ reporter system developed for record-
ing of  CDR2 and  MDR1 expression, an elevation of  CDR2 
expression was measured after doxorubicin addition at dif-
ferent concentrations (Fig. 3). The effect was dose and time 
dependent. We observed that increasing doxorubicin con-
centrations in the assay resulted in a progressive elevation 
of the  lacZ reporter activities. The  lacZ reporter activities 
at a fi xed doxorubicin concentration (20  μ g/ml) reached a 
plateau after 120 – 180 min exposure. No effect of doxoru-
bicin on  MDR1 expression using the  β -galactosidase 
reporter system could be observed confi rming real-time 
PCR results (Fig. 3C).  
 Upregulation of CDR1/2 by doxorubicin correlate with 
increased levels of Cdr1p and Cdr2p in C. albicans 
 We addressed the localization of Cdr1p- and Cdr2p-GFP 
after doxorubicin treatment to correlate elevated mRNA 
levels with enhanced presence of the protein due to doxo-
rubicin treatment. Cdr1p-fusion protein expressed in 
 C. albicans was visualized before and after incubation with 
doxorubicin. Similar to the real-time PCR results, a clear 
effect of doxorubicin was observed for the GFP fusion pro-
teins, especially in the azole-susceptible strains. As shown 
in Fig. 4, an increase of fl uorescence was observed after 
incubation with doxorubicin at therapeutic concentrations 
in the azole-susceptible isolate DSY3098. In the azole-
resistant isolate DSY3098, since the GFP signal is already 
intrinsically high in the absence of doxorubicin, this drug 
could not further increase this intensity. No fl uorescence 
enhancement was observed after incubation with cyclo-
phosphamide. Experiments using Cdr2p-GFP showed 
comparable results with the exception that no fl uorescence © 2011 ISHAM, Medical Mycology, 49, 132–142could be detected in the azole-susceptible isolate DSY3092 
in the absence of doxorubicin as opposed to drug-exposed 
conditions (Fig. 4). 
 When analyzed with anti-Cdr1p and anti-Cdr2p 
antibodies, the doxorubicin induction of Cdr1p and Cdr2p 
could be confi rmed for azole-susceptible isolates (isolates F1, 
B1 and Gu1, Fig. 5), thus again confi rming RT-PCR results. 
In most cases the basal Cdr1p levels of fl uconazole-suscep-
tible isolates were enhanced when doxorubicin was present. 
In contrast, Cdr2p showed no basal expression and was 
detectable only during exposure of isolates to doxorubicin. 
 In azole-resistant isolates, the effect of doxorubicin on 
Cdr1p and Cdr2p levels was less clear. Cdr1p levels in 
isolates F5 and B5, which show as expected high intrinsic 
Mdr1p levels, were almost not elevated in the presence of 
doxorubicin and Cdr2p levels almost absent in the same 
isolates, which contrasts with RT-PCR results (Fig. 1).  
 Overexpression of Cdr1/2p by doxorubicin leads to 
increased fl uconazole resistance in C. albicans 
 MIC values of fl uconazole-susceptible isolates B1, F1 and 
Gu1 were additionally determined either with or without 
the addition of doxorubicin using the microdilution method. 
For all three isolates a shift of the MIC 50 values was 
observed in the presence of doxorubicin (Fig. 6), indicating 
a possible infl uence of doxorubicin in the development of 
the resistance phenotype. 
 However, in spite of the clear induction of effl ux pumps 
by doxorubicin most of the isolates incubated with doxo-
rubicin increased but did not reach the fl uconazole MIC 
values of the resistant strains (without doxorubicin). 
 Discussion 
 This study addressed the question whether cytostatic drugs 
(doxorubicin and cyclophosphamide) could affect azole 
resistance in  C .  albicans . We tested major genes responsible 
for the development of azole resistance in  C. albicans 
( CDR1/2 ,  MDR1 or  ERG11 ) and used two different cyto-
toxic drugs, one including a P-gp substrate (doxorubicin) 
and the other a P-gp non-substrate (cyclophosphamide). A 
signifi cant effect of doxorubicin at therapeutic concentra-
tions was observed for  CDR1 and  CDR2 . Doxorubicin did 
not have any effect on investigated genes other than  CDR1/2. 
On the other hand cyclophosphamide did not induce any of 
the tested drug resistance genes. 
 The induction of  CDR1/2 was detected at the transcrip-
tional and translational level in azole-susceptible isolates, 
however it was not as prominent in azole-resistant isolates. 
We observed that doxorubicin enhanced expression of 
 CDR1/2 in the azole-resistant isolates F5 and B5, in which 
resistance is known to be acquired by  MDR1 upregulation. 
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Fig. 1 Results of  CDR1 ,  CDR2 and  MDR1 gene expression analyses. Clinical isolates were cultivated in the presence or absence of 20  μ g/ml 
doxorubicin or cyclophosphamide, respectively. Gene expressions were normalized against  ACT1 . Left panel: Gene expressions after 90 min of drug 
exposure. Right panel: Gene expressions after 24 h of drug exposure. The y-axes are presented in log2 scale. Results are means of two biological 
replicates (four technical replicates in total)  	 standard deviation.  * P  
 0.05 compared to untreated control (Mann-Whitney test). © 2011 ISHAM, Medical Mycology, 49, 132–142
 Effect of doxorubicin on C. albicans effl ux pumps  139Curiously, this was not verifi ed at the translational 
level (Fig. 5). Several possibilities may explain this dis-
crepancy. Besides the different sensitivities between the 
methods used (RT-PCR vs. immuno-detection), a possible 
incompatibility between the presence of both elevated © 2011 ISHAM, Medical Mycology, 49, 132–142Mdr1p and Cdr1p/Cdr2p levels in the plasma membrane 
of doxorubicin-exposed cells could exist. This hypothesis 
should be tested by future experiments. 
 The induction of  CDR1/CDR2 by doxorubicin can 
therefore be added to the list of other substances mediating Fig. 2 CDR1 and CDR2 gene expression after exposure (20 μg/ml doxorubicin) of the tac1Δ/Δ mutant and the parental strain CAF2-1. Gene expressions 
were normalized against ACT1. (A) Relative CDR1 expression after 90 min and (B) 24 h doxorubicin treatment. (C) Relative CDR2 expression after 
90 min and (D) 24 h doxorubicin treatment. The y-axes are presented in log2 scale. Results are mean of four replicates 	 standard deviation. 
*P 
 0.05 compared to doxorubicin-treated CAF2-1.Fig. 3 MDR1 and CDR2 expression after doxorubicin treatment by a β-galactosidase reporter system. (A) CDR2 induction by doxorubicin is 
concentration dependent. Measurements were performed after 2 h of incubation. (B) Induction of CDR2 by doxorubicin (20μg/ml) is time-dependent. 
(-) and ( D) indicate absence and presence of doxorubicin for the given incubation times. (C) The MDR1-lacZ reporter system was incubated with 
doxorubicin. (- D) and ( D) indicate absence and presence of doxorubicin. Benomyl was used as positive control. Results of all experiments are means 
of three replicates 	 standard deviation.
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Fig. 4 Localization of Cdr1p- and Cdr2p-GFP fusion proteins in C. albicans isolates in absence or presence of 20 μg/ml doxorubicin.this effect including, for example, bioactive compounds 
such as steroids, drugs such as fl uphenazine or antifungal 
agents like terbinafi ne [24,26]. Exposure of  C. albicans to 
these substances results in transient upregulation of 
 CDR1/2 , most probably because these substances are 
themselves substrates for the transporters. Upon transporter 
induction, the substances are effl uxed by  C. albicans , thus 
decreasing their induction potential [26]. It is still unknown 
whether doxorubicin is a substrate for Cdr1p and Cdr2p. 
Intriguingly,  CDR1/2 expression is elevated even after 
24 h of doxorubicin exposure (Fig. 1) and thus suggests that 
this substance may be weakly effl uxed in  C. albicans . 
 Manoharlal and colleagues reported recently that  CDR1 
expression in azole-susceptible clinical isolates of  C. albi-
cans is transient and reversible. It depends mainly on 
increased transcriptional activation of the gene which is 
under the control of  TAC1 . Increased stability of  CDR1 
mRNA in azole-resistant isolates can also contribute to resistance [27]. Here we showed that doxorubicin could 
increase the expression of  CDR1 and  CDR2 in a  TAC1 -
dependent manner (Fig. 2), which is consistent with the 
critical role of  TAC1 in the regulation of both genes. Tran-
sient upregulation of multidrug transporters in  Saccharo-
myces cerevisiae by drugs is thought to be the result of 
activation steps in transcriptional activators via phospho-
rylation and recruitment of co-activators [28,29]. It is likely 
that activation of  TAC1 by doxorubicin may follow similar 
steps. However, other transcriptional elements may par-
ticipate to  CDR1 and  CDR2 regulation. For example, our 
study showed here that basal  CDR1 and  CDR2 expression 
is increased after 24 h incubation in the absence of  TAC1 
(Fig. 2), thus highlighting alternative regulatory circuits of 
these transporters. 
 Induction of multidrug transporters is also a major clin-
ical problem in treating human cancers with conventional 
chemotherapeutic drugs. The phenomenon of multidrug 
resistance (MDR) is mediated in most cases by overexpres-
sion of the human effl ux pump P-glycoprotein (P-gp). 
Recently some studies proposed that this protein could also 
play an important role in delaying apoptosis [26]. MDR-
associated cytotoxic drugs possess the ability to modulate 
transcription levels of the  HsMDR1 gene (Homo sapiens 
MDR1 gene coding for human P-gp). Several drug-responsive 
elements have been identifi ed within the  HsMDR1 gene 
promoter and the inducibility of the gene via  HsMDR1 
promoter sequences by classical MDR-associated cyto-
static drugs such as doxorubicin, vincristine or actinomy-
cin D has been be shown. This phenomenon is responsible 
for MDR during chemotherapy [30]. Fig. 5 Cdr1p, Cdr2p and Mdr1p detection after incubation with 
doxorubicin for 90 min. The left panel shows results of fl uconazole-
susceptible C. albicans isolates. The right panel shows the results of 
fl uconazole-resistant C. albicans isolates. () doxorubicin induction 
(20 μg/ml); (-) untreated control. The Coomassie Blue stained signals 
were revealed after protein transfer on the nitrocellulose membrane and 
show that equivalent protein amounts were loaded in each sample.© 2011 ISHAM, Medical Mycology, 49, 132–142
 Effect of doxorubicin on C. albicans effl ux pumps  141 One of the consequences of the induction of multidrug 
transporters by specifi c compounds is that they antagonize 
the activity of antifungal agents [31]. Development of 
resistance can also be induced  in vitro by adding fl ucon-
azole to a culture suspension containing  C. albicans strain 
ATCC36082 after serial passaging in the drug-containing 
medium [32]. The resistance mechanisms seem to be 
inducible by a fl uconazole therapy and reversible after © 2011 ISHAM, Medical Mycology, 49, 132–142stopping of this therapy [32,33]. Most of the strains inves-
tigated here incubated with doxorubicin increased their 
fl uconazole MICs. Even if this MIC increase did not reach 
the MIC values of resistant strains, the apparent antago-
nism between doxorubicin and fl uconazole could be of 
clinical relevance. When antifungal treatment of  Candida 
infections occurs simultaneously with anticancer chemo-
therapy, then it is possible that treatment effi cacy could be 
compromised. Experimental infection models could be 
used in the future to address this hypothesis. 
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